By Fineline Cube 
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), has formed a strategic partnership with Israel-based Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) to jointly advance the commercialization of Treanda (bendamustine) in the mainland China market. The collaboration aims to expand market access and address unmet clinical needs in indolent B-cell non-Hodgkin lymphoma (NHL).
Partnership Structure
| Component | Details |
|---|---|
| Chinese Partner | Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) |
| Parent Company | Sino Biopharmaceutical Ltd. (HKG: 1177) |
| International Partner | Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) |
| Asset | Treanda (bendamustine) – lymphoma treatment |
| Territory | Mainland China |
| Regulatory Status | Approved in China since 2018 |
| Indication | Indolent B-cell NHL progressing during/after rituximab-containing regimens |
Product Profile & Market Position
- Origin: Developed and originated by Teva Pharmaceutical Industries
- Approval Milestone: Received Chinese regulatory approval in 2018
- Therapeutic Area: Hematologic oncology – specifically indolent B-cell non-Hodgkin lymphoma
- Patient Population: Patients with disease progression during or after rituximab or rituximab-containing regimens
- Clinical Significance: Addresses critical treatment gap in relapsed/refractory indolent NHL setting
Commercial Responsibilities
CTTQ Role
- Primary Responsibility: Lead commercialization and promotion activities in mainland China
- Market Expertise: Leverage established oncology sales infrastructure and hospital relationships
- Local Capabilities: Navigate China’s complex healthcare system and reimbursement landscape
Joint Collaboration Areas
- Market Expansion: Broaden geographic and institutional reach across China
- Terminal Coverage: Enhance penetration in key treatment centers and hospitals
- Patient Access: Improve affordability and availability through strategic pricing and distribution initiatives
- Clinical Education: Support physician awareness and appropriate patient identification
Strategic Rationale
For Sino Biopharmaceutical/CTTQ
- Oncology Portfolio Enhancement: Strengthens position in hematologic malignancies segment
- International Partnership: Validates CTTQ’s commercial capabilities among global pharmaceutical companies
- Revenue Diversification: Adds established oncology product with proven market demand
For Teva Pharmaceutical
- China Market Access: Leverages CTTQ’s local expertise to maximize commercial potential
- Operational Efficiency: Reduces need for direct commercial infrastructure investment in China
- Focus Optimization: Allows Teva to concentrate resources on core global markets while maintaining China presence
Market Context
- China NHL Market: Estimated at RMB 3.5 billion ($500 million) annually for indolent B-cell NHL treatments
- Treatment Landscape: Limited options for rituximab-refractory patients create premium positioning opportunity
- Reimbursement Status: National Reimbursement Drug List (NRDL) inclusion enhances patient access and market penetration potential
- Competitive Environment: Established bendamustine market with room for expanded utilization through improved access initiatives
Financial Terms
Specific financial terms of the commercialization agreement were not disclosed. Typical arrangements in such partnerships include upfront payments, milestone achievements, and royalty structures based on sales performance.
Forward‑Looking Statements
This brief contains forward-looking statements regarding commercial expectations, market expansion, and partnership benefits for Treanda in China. Actual results may differ due to risks including market competition, reimbursement changes, regulatory developments, and competitive dynamics.-Fineline Info & Tech